

Agenda subject to change prior to July 11 meeting.

Prescription Drug Affordability Board Meeting Agenda Friday, July 11, 2025 from 10:00 am - 1:00 pm

Zoom Meeting Information:

https://us06web.zoom.us/meeting/register/tZcvfu2tqD4pGdLLE78FEqIlouhgDE0tavoh#/registration

Call to Order, Roll Call, & Minutes Approval 10:00 - 10:05 am

Board Member & Director Updates 10:05 - 10:10 am

Board Business 10:10 - 11:10 am

• The Board may meet in Executive Session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S.

Public Comment 11:10 - 11:30 am

Comments will be limited to 2 minutes per person or organization.

Break 11:30 - 11:40 am

Rulemaking Hearing

11:40 am - 1:00 pm

Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel

- Rule Introduction
- Witness Testimony
 - Witness testimony will be limited to three minutes per person. The Board may ask questions to the person testifying regarding their testimony. The time limit will not count towards answering any of the Board's questions. We will try to get to every testimony during the rulemaking hearing. However, if you are not selected to speak due to time constraints, please submit written testimony and sign up to testify at the next rulemaking hearing.
- Board Deliberation

The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.

The Board may meet in Executive Session to receive legal advice pursuant to section 24-6-402(3)(a)(II), C.R.S.



Agenda subject to change prior to July 11 meeting.

If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at dora ins pdab@state.co.us.

Councilmembers of the Prescription Drug Affordability Advisory Council may attend the July 11, 2025, Prescription Drug Affordability Board Meeting and may participate in the meeting, which may include providing public comment.